IOL Chemicals & Pharmaceuticals Limited has scheduled an analyst and investor conference call to discuss its financial performance for the third quarter and nine months ended December 31, 2025. The company announced this development through a regulatory filing dated February 4, 2026, in compliance with SEBI listing requirements.

Earnings Call Details

The conference call is scheduled for February 12, 2026, at 3:00 PM IST, providing stakeholders with insights into the company's Q3 and 9M FY26 financial results. The announcement was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Management Participation

The earnings call will feature participation from key members of IOL Chemicals and Pharmaceuticals' senior management team. The company has confirmed the presence of four senior executives who will address investor queries and provide detailed insights into the financial performance.

Access Information

Investors and analysts can participate in the conference call through multiple access numbers, including both domestic and international toll-free options. The company has provided comprehensive connectivity options to ensure broad participation.

Domestic Access Numbers:

• Primary: +91 22 6280 1550
• Secondary: +91 22 7115 8378

International Toll-Free Numbers:

• Hong Kong: 800 964 448
• Singapore: 800 101 2045
• USA: 1866 746 2133
• UK: 0808 101 1573

Coordination and Contact Details

MUFG Intime India Pvt. Ltd. is serving as the investor relations coordinator for this earnings call. Participants requiring additional information or assistance can contact Ms. Prachi Ambre at +91 83559 85370 or via email at prachi.ambre@in.mpms.mufg.com . The company has also provided a pre-registration link for participants to ensure smooth access to the conference call.

The regulatory filing was signed by Abhay Raj Singh, Sr. Vice President & Company Secretary, and submitted to both the National Stock Exchange of India Ltd. (Security Symbol: IOLCP) and BSE Limited (Security Code: 524164) on February 4, 2026.

IOL Chemicals & Pharmaceuticals Limited has initiated the process to strike off its wholly owned subsidiary IOL Life Sciences Limited from the register of companies. The company filed the application with the Registrar of Companies on January 27, 2026, under Section 248 of the Companies Act, 2013, as disclosed in its regulatory filing to the stock exchanges.

Strike-off Application Details

The application for striking off IOL Life Sciences Limited has been submitted pursuant to Section 248 of the Companies Act, 2013, read with applicable rules. The strike-off process is subject to receipt of necessary approvals from the Ministry of Corporate Affairs, Registrar of Companies, and other statutory authorities as applicable.

Financial Position of Subsidiary

IOL Life Sciences Limited had minimal financial contribution to the parent company's operations. The subsidiary's financial position as on March 31, 2025, reflects its dormant status:

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular SEBI/HO/CFD/-PoD-1/P/CIR/2023/123 dated July 13, 2023. The company has provided all required details in compliance with regulatory requirements.

Transaction Classification

The strike-off application does not involve any sale or disposal transaction, as clarified in the regulatory filing. Key aspects of the process include:

• No agreement for sale has been entered into
• No consideration is being received from the strike-off
• The transaction does not fall within related party transactions
• No buyers are involved in the process

The strike-off represents a corporate restructuring move to eliminate a dormant subsidiary that has not contributed to the company's operations or financial performance. IOL Chemicals and Pharmaceuticals Limited continues to focus on its core chemical and pharmaceutical operations while streamlining its corporate structure through this subsidiary elimination process.